Treatment of Hypertension - Full Text View

Sponsor:	National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:	National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:	NCT00000484

Purpose

To determine whether the long-term treatment of essential hypertension without significant target organ disease materially influenced mortality and/or cardiovascular renal morbidity.

Condition	Intervention	Phase
Cardiovascular Diseases Heart Diseases Hypertension Vascular Diseases	Drug: chlorothiazide Drug: Rauwolfia alkaloids	Phase III

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Placebo Control

Resource links provided by NLM:

MedlinePlus related topics: Heart Diseases High Blood Pressure Vascular Diseases

Drug Information available for: Chlorothiazide Chlorothiazide sodium

U.S. FDA Resources

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date:

April 1966

Detailed Description:

BACKGROUND:

This grant-supported, cooperative, fixed-protocol clinical study was initiated in 1966 and followed a cooperative study of the treatment of renal hypertension initiated in 1960 to evaluate the relative efficacy of several recognized drug regimens for reduction of blood pressure. Six centers (USPHS hospitals) and a coordinating center were involved in the trial.

DESIGN NARRATIVE:

Randomized, double-blind, fixed sample. Three hundred and eighty nine eligible patients were assigned to drug therapy consisting of chlorothiazide plus Rauwolfia serpentina or to placebo.

Eligibility

Ages Eligible for Study:	21 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Men and women, ages 21-55. Mild essential hypertension (diastolic blood pressure over 90 mm Hg.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000484

Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

Investigator:	Anthony Damato	USPHS Hospital
Investigator:	Richard Thurm	USPHS Hospital
Investigator:	Christfried Urner	USPHS Hospital
Investigator:	John Vaillancourt	USPHS Hospital
Investigator:	J. Warbasse	USPHS Hospital
Investigator:	Robert Wells	USPHS Hospital

More Information

Publications:

[No authors listed] Morbidity and mortality in mild essential hypertension. Circ Res. 1972 Sep;31(9):Suppl 2:110-24. No abstract available.

U.S. Public Health Service Hospitals Cooperative Study Group. Smith WM, et al: Intervention Trial in Mild Hypertension. Epidemiology and Control of Hypertension. Paul, O (Ed.), Symposia Specialists, Miami, l975, pp. 46l-483.

Elharrar V, Foster PR, Jirak TL, Gaum WE, Zipes DP. Alterations in canine myocardial excitability during ischemia. Circ Res. 1977 Jan;40(1):98-105.

Smith WM. Mild essential hypertension: benefit of treatment: discussion. Ann N Y Acad Sci. 1978 Mar 30;304:74-80. No abstract available.

Smith WM, Edlavitch SA, and Krushat WM: U.S. Public Health Service Hospitals Intervention Trial in Mild Hypertension. Hypertension, Determinants, Complications, and Intervention. Onesti G, and Klimt C, (Eds.), Grune & Stratton, New York, l979, pp. 38l-399.

Smith WM: Hypertension--Effectiveness of Early Treatment in Preventing Sequellae. Proceedings of the Eisenhower Medical Center. Preventive Interventions in the Practice of Medicine, Spring, l979, pp. 8l-87.

Smith WM, Edlavitch SA, and Krushat WM: Prevention of Stroke in Mild Hypertension: Public Health Service Hospitals Trial. Perspectives in Cardiovascular Research, Vol. 4. Prophylactic Approach to Hypertensive Diseases, Yamori Y, Lovenberg W, and Freis ED, (Eds.), Raven Press, New York, l979, pp. 53-62.

Study ID Numbers:	3
Study First Received:	October 27, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000484 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Heart Diseases
Molecular Mechanisms of Pharmacological Action
Chlorothiazide
Diuretics
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Vascular Diseases
Cardiovascular Agents

Antihypertensive Agents
Pharmacologic Actions
Membrane Transport Modulators
Natriuretic Agents
Therapeutic Uses
Cardiovascular Diseases
Hypertension

ClinicalTrials.gov processed this record on February 08, 2010